AR023008A1 - 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides - Google Patents

21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides

Info

Publication number
AR023008A1
AR023008A1 ARP980104727A ARP980104727A AR023008A1 AR 023008 A1 AR023008 A1 AR 023008A1 AR P980104727 A ARP980104727 A AR P980104727A AR P980104727 A ARP980104727 A AR P980104727A AR 023008 A1 AR023008 A1 AR 023008A1
Authority
AR
Argentina
Prior art keywords
oxidoprogesterone
glucocorticoids
excess
hydroxi
treat
Prior art date
Application number
ARP980104727A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR023008A1 publication Critical patent/AR023008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha descubierto el esteroide conformado de manera altamente inclinada 21-hidroxi-6,19-oxidoprogesterona (21OH-6OP) como un selectivo antiglucocorticoideque carece virtualmente de propiedades mineralococorticoides o glucocorticoides tanto como su afinidad para el MR o el PR y se usa para el tratamiento deenfermedades asociadas con un exceso de glucocorticoides en el cuerpo, tales como el síndrome de Cushing o la depresion.
ARP980104727A 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides AR023008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (en) 1997-09-23 1997-09-23 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid

Publications (1)

Publication Number Publication Date
AR023008A1 true AR023008A1 (es) 2002-09-04

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104727A AR023008A1 (es) 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides

Country Status (13)

Country Link
US (1) US6303591B1 (es)
EP (2) EP0903146A1 (es)
AR (1) AR023008A1 (es)
AT (1) ATE215373T1 (es)
AU (1) AU738522B2 (es)
CA (1) CA2303817C (es)
DE (1) DE69804659T2 (es)
DK (1) DK1033990T3 (es)
ES (1) ES2172937T3 (es)
IL (1) IL135232A (es)
PT (1) PT1033990E (es)
WO (1) WO1999015181A1 (es)
ZA (1) ZA988674B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304203B6 (cs) 1999-04-30 2014-01-02 Pfizer Products Inc. Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
US7053228B2 (en) * 2000-09-18 2006-05-30 Applied Research Systems Ars Holding N.V. Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
DE60124289T2 (de) * 2000-09-18 2007-09-06 Applied Research Systems Ars Holding N.V. Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
ATE303369T1 (de) 2000-10-30 2005-09-15 Pfizer Prod Inc Glucocorticoid rezeptor modulatoren
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
MX2017011885A (es) 2015-03-30 2018-02-19 Corcept Therapeutics Inc Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
JP2022515528A (ja) * 2018-12-28 2022-02-18 パンダ コンサルティング エルエルシー 短時間作用型選択的糖質コルチコイド受容体モジュレーター

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
PT1023074E (pt) * 1997-10-06 2006-12-29 Trustees Leland Stanford Junio Métodos para tratamento de psicose associada a disfunção relacionada com glucocorticóides

Also Published As

Publication number Publication date
US6303591B1 (en) 2001-10-16
DE69804659T2 (de) 2002-10-02
EP0903146A1 (en) 1999-03-24
CA2303817A1 (en) 1999-04-01
WO1999015181A1 (en) 1999-04-01
PT1033990E (pt) 2002-07-31
DE69804659D1 (de) 2002-05-08
EP1033990A1 (en) 2000-09-13
IL135232A0 (en) 2001-05-20
IL135232A (en) 2005-05-17
EP1033990B1 (en) 2002-04-03
ATE215373T1 (de) 2002-04-15
ES2172937T3 (es) 2002-10-01
DK1033990T3 (da) 2002-07-08
ZA988674B (en) 1999-06-28
CA2303817C (en) 2008-04-01
AU1334199A (en) 1999-04-12
AU738522B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AR023008A1 (es) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) para tratar el exceso de glucocorticoides
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
MY131522A (en) PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
UA43378C2 (uk) Композиція для лікування респіраторного дистрес-синдрому новонароджених та респіраторного дистрес-синдрому дорослих
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
AU2386201A (en) Substituted sapogenins and their use
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BR0208533A (pt) Derivados de sapogenina, sìntese e uso dos mesmos e processos com base em seu uso
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
NZ334786A (en) Use of a Hydrogen, Potassium-ATPase inhibitor in the treatment of nasal polyps, asthma and Widal's syndrome
DE60104194D1 (de) Kombination der progesteron und mifepristone für krebs-therapie
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
BR0115364A (pt) Tratamento de disfunção sexual
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
DE69525181D1 (de) Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
ES2171080T3 (es) Composicion para la mejora de la fertilidad y su aplicacion.
MD1204G2 (ro) Biozidă (25R)-spirost-5-en-3{beta}, 27-diol-27-O-(3-hidroxi-3metilglutaroil) ce posedă proprietăţi fungicide
GB9723824D0 (en) Cytostatic agents
UA22066C2 (uk) Спосіб безмедикамеhтозhого лікуваhhя гіпертоhічhої хвороби та пристрій для його здійсhеhhя
AR032371A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
KR970005296A (ko) 편도선염 치료제
ES18321U (es) Braguero elástico para herniario.

Legal Events

Date Code Title Description
FB Suspension of granting procedure